Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cgh.2020.07.050 http://scihub22266oqcxt.onion/10.1016/j.cgh.2020.07.050 32721580!7381904!32721580     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Gastroenterol+Hepatol 2020 ; 18 (12): 2835-2836 Nephropedia Template TP {{tp|p=32721580|t=2020. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019 |pdf=|usr=}}{{32721580}} gab.com Text Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019 JO: Clin Gastroenterol Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=32721580 #FOAvip Remdesivir is a nucleotide analog prodrug with antiviral activity against a broad spectrum of human coronavirus in cell cultures and mouse models including severe acute respiratory syndrome-associated coronavirus 2. Recently, the Food and Drug Agency (FDA) and the European Medicines Agency (EMA) recommended remdesivir for the treatment of patients hospitalized with severe coronavirus disease 2019 (COVID-19) infection.(1)(,)(2) In the remdesivir clinical development program, some cases have raised concerns regarding potential hepatobiliary disorders associated with remdesivir, including in healthy volunteers and patients with COVID-19.(3) In cohort studies of patients hospitalized for severe COVID-19 who were treated with compassionate-use remdesivir, elevated hepatic enzymes were the most frequent adverse drug reaction reported.(4)(,)(5) In the first randomized, double-blind, placebo-controlled clinical trial assessing the effect of intravenous remdesivir in adults admitted to hospital with severe COVID-19 (n = 237), a higher proportion of remdesivir recipients than placebo recipients had dosing prematurely stopped by the investigators because of adverse events including aminotransferase or bilirubin increases (3 versus 0).(6) Although there is no signal from the available data of severe hepatotoxicity or drug-induced liver injury in clinical trials, the number of patients exposed to remdesivir was too limited. Therefore, there is an urgent need to investigate the hepatic safety profile associated with remdesivir in COVID-19 patients. Twit Text FOAVip Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019 ????Clin Gastroenterol Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=32721580 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32721580 #FOAvip English Wikipedia <ref>{{Cite pmid|32721580}}</ref> Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019 #MMPMID32721580 Montastruc F; Thuriot S; Durrieu G Clin Gastroenterol Hepatol 2020[Nov]; 18 (12): 2835-2836 PMID32721580show ga Remdesivir is a nucleotide analog prodrug with antiviral activity against a broad spectrum of human coronavirus in cell cultures and mouse models including severe acute respiratory syndrome-associated coronavirus 2. Recently, the Food and Drug Agency (FDA) and the European Medicines Agency (EMA) recommended remdesivir for the treatment of patients hospitalized with severe coronavirus disease 2019 (COVID-19) infection.(1)(,)(2) In the remdesivir clinical development program, some cases have raised concerns regarding potential hepatobiliary disorders associated with remdesivir, including in healthy volunteers and patients with COVID-19.(3) In cohort studies of patients hospitalized for severe COVID-19 who were treated with compassionate-use remdesivir, elevated hepatic enzymes were the most frequent adverse drug reaction reported.(4)(,)(5) In the first randomized, double-blind, placebo-controlled clinical trial assessing the effect of intravenous remdesivir in adults admitted to hospital with severe COVID-19 (n = 237), a higher proportion of remdesivir recipients than placebo recipients had dosing prematurely stopped by the investigators because of adverse events including aminotransferase or bilirubin increases (3 versus 0).(6) Although there is no signal from the available data of severe hepatotoxicity or drug-induced liver injury in clinical trials, the number of patients exposed to remdesivir was too limited. Therefore, there is an urgent need to investigate the hepatic safety profile associated with remdesivir in COVID-19 patients. |*Betacoronavirus[MESH] |Adenosine Monophosphate/adverse effects/*analogs & derivatives/therapeutic use[MESH] |Alanine/adverse effects/*analogs & derivatives/therapeutic use[MESH] |Antiviral Agents/adverse effects/therapeutic use[MESH] |COVID-19[MESH] |Chemical and Drug Induced Liver Injury/*epidemiology/etiology[MESH] |Coronavirus Infections/*drug therapy/epidemiology[MESH] |Europe/epidemiology[MESH] |Female[MESH] |Humans[MESH] |Incidence[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/epidemiology[MESH] |SARS-CoV-2[MESH]Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019 (epmc).pdf DeepDyve Pubget Overpricing